腺苷
癌症研究
免疫系统
免疫疗法
肿瘤微环境
髓源性抑制细胞
CD8型
T细胞
腺苷脱氨酶
医学
免疫学
药理学
癌症
抑制器
内科学
作者
Omar Sadi Sarkar,Howard Donninger,Numan Al Rayyan,Lewis C. Chew,Bryce F. Stamp,Xiang Zhang,Aaron G. Whitt,Chi Li,Melissa Barousse Hall,Robert A. Mitchell,Alfred Zippelius,John W. Eaton,Jason Alan Chesney,Kavitha Yaddanapudi
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2023-06-30
卷期号:9 (26): eadg3736-eadg3736
被引量:83
标识
DOI:10.1126/sciadv.adg3736
摘要
Abstract Although immune checkpoint inhibitor (ICI) therapy has provided robust results in many cancer types such as melanoma and lung cancer, a large percentage of patients remain unresponsive to this therapy. Emerging evidence strongly suggests that one of the contributing factors in ICI resistance is monocytic myeloid derived suppressor cells (M-MDSCs) that accumulate in late-stage cancer patients. These M-MDSCs are a subset of innate immune cells and possess potent immunosuppressive activity against T lymphocytes. Here we provide evidence of a mechanism by which CD73-expressing M-MDSCs in the tumor microenvironment (TME) exhibit superior T cell suppressor function via adenosine. We show that tumor-derived PGE 2 , a prostaglandin frequently found at high levels in the TME, directly induces CD73 expression in M-MDSCs by initiating a signaling pathway that is mediated by both Stat3 and CREB. The resulting CD73 overexpression induces elevated levels of adenosine, a nucleoside with strong T cell suppressive activity, culminating in the suppression of CD8 + T cell-mediated anti-tumor responses. We also show that depletion of adenosine in the TME by the repurposed drug PEGylated Adenosine Deaminase (PEG-ADA) increases CD8 + T cell anti-tumor activity and enhances response to ICI therapy in preclinical models of cancer. Our results suggest that use of PEG-ADA is a viable therapeutic option to overcome ICI therapeutic resistance in advanced cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI